|
End-of-day quote
Shanghai S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 13.82 CNY | +1.54% |
|
+0.29% | -8.29% |
| 10-26 | Citi Adjusts Tasly Pharmaceutical Group's Price Target to 16.50 Yuan | MT |
| 10-15 | Huachuang Securities Starts Tasly Pharmaceutical Group at Add with 17.20 Yuan Price Target | MT |
Company Valuation: Tasly Pharmaceutical Group Co., Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,778 | 15,988 | 25,427 | 21,603 | 22,514 | 20,646 | - | - |
| Change | - | -32.76% | 59.04% | -15.04% | 4.22% | -8.29% | - | - |
| Enterprise Value (EV) 1 | 23,086 | 14,968 | 23,635 | 20,197 | 22,465 | 19,102 | 14,934 | 18,277 |
| Change | - | -35.16% | 57.9% | -14.55% | 11.23% | -14.97% | -21.82% | 22.38% |
| P/E | 10.1x | -63.3x | 23.6x | 22.6x | 20.4x | 16.4x | 13.3x | 11.5x |
| PBR | 1.83x | 1.3x | 2.06x | 1.81x | 1.82x | 1.57x | 1.44x | 1.32x |
| PEG | - | 1x | -0x | -2x | 1.3x | 1.2x | 0.6x | 0.8x |
| Capitalization / Revenue | 2.99x | 1.86x | 2.93x | 2.54x | 2.73x | 2.41x | 2.23x | 2.06x |
| EV / Revenue | 2.9x | 1.74x | 2.72x | 2.38x | 2.73x | 2.23x | 1.61x | 1.82x |
| EV / EBITDA | 7.32x | 50.8x | 14.2x | 12.8x | 12.3x | 8.88x | 6.43x | 6.96x |
| EV / EBIT | 8.45x | -97.9x | 19.2x | 18.8x | 16.6x | 11.5x | 8.41x | 9.08x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.33 | 0.33 | 0.33 | 0.2 | 0.1 | 0.3478 | 0.458 | 0.558 |
| Rate of return | 2.08% | 3.07% | 1.94% | 1.38% | 0.66% | 2.52% | 3.31% | 4.04% |
| EPS 2 | 1.57 | -0.17 | 0.72 | 0.64 | 0.74 | 0.8441 | 1.043 | 1.202 |
| Distribution rate | 21% | -194% | 45.8% | 31.3% | 13.5% | 41.2% | 43.9% | 46.4% |
| Net sales 1 | 7,952 | 8,593 | 8,674 | 8,498 | 8,236 | 8,576 | 9,272 | 10,024 |
| EBITDA 1 | 3,153 | 294.6 | 1,663 | 1,578 | 1,820 | 2,150 | 2,324 | 2,626 |
| EBIT 1 | 2,733 | -153 | 1,228 | 1,076 | 1,350 | 1,666 | 1,775 | 2,014 |
| Net income 1 | 2,359 | -256.5 | 1,071 | 955.6 | 1,105 | 1,263 | 1,558 | 1,798 |
| Net Debt 1 | -691.9 | -1,020 | -1,792 | -1,406 | -48.5 | -1,544 | -5,712 | -2,369 |
| Reference price 2 | 15.85 | 10.76 | 17.02 | 14.46 | 15.07 | 13.82 | 13.82 | 13.82 |
| Nbr of stocks (in thousands) | 1,500,163 | 1,485,873 | 1,493,950 | 1,493,950 | 1,493,950 | 1,493,950 | - | - |
| Announcement Date | 3/30/22 A | 3/27/23 A | 4/15/24 A | 2/24/25 A | 2/6/26 A | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.37x | 2.23x | 8.88x | 2.52% | 3.1B | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 29.85x | 6.87x | 20.37x | 2.06% | 426.5B | |
| Weighted average by Cap. | 37.14x | 8.83x | 22.80x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 600535 Stock
- Valuation Tasly Pharmaceutical Group Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
